ISPOR 2nd Latin America Conference Research Presentation Award Recipients

The  ISPOR  Research  Presentation  Awards  were  established  in  1998  to recognize the scientific merit of podium and poster presentations of the ISPOR  Annual  International  Meetings,  Annual  European  Congresses,  and Asia-Pacific and Latin America Conferences.

At the ISPOR 2nd Latin America Conference, the ISPOR Research Presenta-tion Award judges evaluated 45 podium presentations and nominated post-ers from 200 poster presentations. All podium presentations are considered for an award. Poster presentations in the top 10%, based on abstract review score, are considered and eligible for a poster presentation award.

Evaluations of scientific merit were based upon the following criteria:

• Background provides appropriate perspective / context for the subject
• Objectives / research questions are clearly stated
• Research design / methods / modeling is appropriate and transparent (scores on this will determine winners in case of ties)
• Data sources and/or sampling procedures are clear and appropriate
• Data analyses are appropriate
• Research objectives are met/addressed
• Implications of findings are discussed
• Factual information is kept separate from interpretations or implications
• Abstract is presented in an unbiased manner
• Clarity of presentation

ISPOR Best Poster Research Presentations

PCN26: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VS SORAFENIB AND BEVACIZUMAB + INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO Salinas-Escudero G1, Contreras-Hernandez I2, Mould-Quevedo J3, 1Hospital Infantil de México Federico Gómez, Mexico City, Mexico, 2Social Security Mexican Institute, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico

PIH1: MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN ADULTOS MAYORES ATENDIDOS EN ATENCIóN PRIMARIA DE SALUD
García J1, Jirón M1, Ruíz I1, Santibañez M2, 1Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile, 2Departamento de Salud, Comuna de San Ramón, Santiago, Chile

PIN8: EVALUACIÓN DEL IMPACTO EPIDEMIOLÓGICO Y ECONÓMICO DE LA INTRODUCCIÓN DE LA VACUNA DE ROTAVIRUS EN EL PAÍS DE COLOMBIA de La Hoz F1, Alvis N2, Cediel N3, Narváez J1, Orozco J4, Alvis L2 1Universidad Nacional de Colombia, Bogotá D.C, Colombia, 2Universidad de Cartagena, Cartagena, Colombia, 3Università degli Studi di Torino, Grugli-asco, Torino, Italy, 4Ayges Consultoría S.A, Cartagena, Colombia

PRS1: TOBACCO AND INCOME LEVEL: A SYSTEMATIC REVIEW AND META-ANALYSIS
Ciapponi A1, Bardach A2, Glujovsky D1, Aruj P1, Mazzoni A1, Comandé D1, Gibbons L3, Linetzky B4, Casetta B5, 1Instituto de Efectividad Clínica y
Sanitaria (IECS), Buenos Aires, Argentina, 2Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Buenos Aires, Argentina, 3Institute of Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, 4Ministerio de Salud - Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 5Ministerio de Salud, Buenos Aires, Argentina

PRS3: A MICROSIMULATION ECONOMIC MODEL TO EVALUATE THE DIS-EASE BURDEN ASSOCIATED WITH SMOKING IN ARGENTINA Pichon-Riviere A1, Augustovski FA2, Colantonio L3, Bardach A3, Rubinstein A2, 1Instituto de Efectividad Clínica y Sanitaria (IECS), Ciudad Autónoma de Buenos Aires, Argentina, 2Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, 3Instituto de Efectividad Clínica y Sanitaria (IECS), Ciudad de Buenos Aires, Buenos Aires, Argentina

PSY6: USTEKINUMAB IS ASSOCIATED WITH SIGNIFICANT IMPROVE-MENTS IN OVERALL HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PSORIASIS PATIENTS
Schenkel B1, Langley R2, Wang Y3, Kimball A4, 1J&J Pharmaceutical Services LLC, Malvern, PA, USA, 2Dalhousie University, Halifax, NS, Canada, 3Centocor Clinical Research and Development, Inc, Malvern, PA, USA, 4Brigham and Women’s Hospital, Boston, MA, USA

ISPOR Best Podium Research Presentations

CO2: PRESCRIPCIÓN DE MEDICAMENTOS POTENCIALMENTE INAPROPIA-DOS EN ADULTOS MAYORES HOSPITALIZADOS
Jirón M1, Escobar L1, Orellana S1, Jara P1, Oyarzún X1, Arriagada L2, Griñen H1, 1Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile, 2Hospital Clínico de la Universidad de Chile, Santiago, Chile

CS3: UN MODELO DE COSTO-UTILIDAD DEL TRASPLANTE RENAL EN COLOMBIA
Rosselli D, Independiente, Bogotá, DC, Colombia

CS14: ASSESSMENT OF THE ECONOMICAL IMPACT OF NON-PERSIS-TENCE WITH ANTIDEPRESSANT TREATMENTS USING THE ADMINISTRA-TIVE CLAIMS DATABASE OF QUEBEC (CANADA)
Beland SG1, Moride Y1, Pariente A2, Tournier M2, Lebeau M1, Galbaud du Fort G3, Crott R4, Ducruet T3, 1Université de Montreal, Montréal, QC, Canada, 2Victor Segalen Bordeaux 2, Bordeaux, Bordeaux, France, 3McGill University, Montreal, QC, Canada, 4Université Catholique de Louvain, Brussels, Belgium

CS16: COST UTILITY OF POSACONAZOLE VERSUS FLUCONAZOLE/ITRA-CONAZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS IN MEXICO Rely K1, Pierre KA2, Salinas EG3, 1Network on the Economic Evaluation

of Healthcare Programmes and its Applications to Decision Making in Latin American Countries, Mexico DF, Mexico, 2Johns Hopkins University,

Bloomberg School of Public Health, Baltimore, MD, USA, 3Hospital Infantil de México Federico Gómez, Mexico DF, Mexico

CS19: AUDITORIA BASEADA EM EVIDÊNCIAS (ABE): IMPACTO NO CUSTO DO TRATAMENTO QUIMIOTERÁPICO AP”S 3 ANOS DE IMPLANTAÇÃO

Clark LG, Alves AF, Castro AP, Santos FS, Clark O, Engel T, Paladini L, Peg-oretti B, Faleiros E, Evidencias Medicas, Campinas, São Paulo, Brazil
CS20: RELATIONSHIP BETWEEN ADHERENCE LEVEL TO STATINS AND CLINI-CAL ISSUES AND HEALTH CARE COSTS IN REAL LIFE CLINICAL SETTING
Dragomir A1, Côté R2, Perreault S1, 1University of Montreal, Montréal, QC, Canada, 2McGill University, Montréal, QC, Canada

  Issues Index | 2009 Issues Index